Stock TECH BIO-TECHNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-01-24 pm EST 		5-day change 1st Jan Change
77.05 USD +0.18% Intraday chart for Bio-Techne Corporation +1.61% +6.97%
Jan. 14 Bio-Techne Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM
Jan. 10 Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine CI

Highlights

Search
See the results
Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
Jan. 10
 CI
Bio-Techne Prevails in Second Reverse Engineering Claim by Miltenyi Biotec; Shares Up
Jan. 07
 MT
Bio-Techne, Waters Strike Co-Marketing, Co-Promotion Deal
Dec. 19
 MT
Bio-Techne Signs Distribution Deal With MedSanTek to Expand Product Reach in Turkey
Dec. 12
 MT
Medsantek Co. Partners with Bio-Techne Corporation to Bring World-Class Products and Diagnostics in Turkey and Azeri Markets
Dec. 12
 CI
Bio-Techne's Select Fetal Bovine Serum Product Rights, Inventory Acquired by Gemini Bioproducts
Nov. 25
 MT
Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation.
Nov. 24
 CI
Bio-Techne Signs Distribution Deal With Leader Life Sciences
Nov. 20
 MT
Bio-Techne Corporation Announces New Distribution Agreement with Leader Life Sciences
Nov. 20
 CI
Bio-Techne Corporation and ALZpath, Inc Announce Strategic Partnership to Advance Neurodegenerative Disease Research
Nov. 18
 CI
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo
Nov. 14
 CI
Ex-dividend day
Nov. 07
 FA
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer 39Th Annual Meeting
Nov. 06
 CI
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.
Nov. 05
 CI
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data
Nov. 05
 CI
Scotiabank Adjusts Bio-Techne's Price Target to $88 From $83
24-10-31
 MT
Baird Adjusts Bio-Techne's Price Target to $84 From $82
24-10-31
 MT
Stifel Adjusts Bio-Techne's Price Target to $75 From $65
24-10-31
 MT
RBC Adjusts Bio-Techne's Price Target to $79 From $77
24-10-31
 MT
Bio-Techne Keeps Quarterly Dividend at $0.08 a Share, Payable Nov. 22 to Shareholders of Record as of Nov. 11
24-10-30
 MT
Bio-Techne Fiscal Q1 Adjusted Earnings, Net Sales Rise
24-10-30
 MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Posts Q1 Revenue $289.5M
24-10-30
 MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q1 EPS $0.42
24-10-30
 MT
Bio-Techne Corporation Reports Earnings Results for the First Quarter Ended September 30, 2024
24-10-30
 CI
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024
24-10-30
 CI
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TECH Stock
  4. News Bio-Techne Corporation
  5. Highlights